Ascentage Pharma Group International reported no changes to its share capital structure for June 2026, according to its Monthly Return to Hong Kong Exchanges and Clearing Limited dated 7 July 2026.

Key points:

• Authorised share capital stood unchanged at 500.00 million ordinary shares with a par value of USD 0.0001 each, representing total authorised capital of USD 50,000.

• Issued share capital remained flat at 373.56 million ordinary shares. The company held no treasury shares, and no new shares were issued or cancelled during the month.

• Public float met the Main Board’s minimum 25% threshold as of 30 June 2026, ensuring continued compliance with Hong Kong Listing Rules.

• Equity incentive activity was limited to the Post-IPO Share Option Scheme, which granted 0.69 million new options, bringing total outstanding options under that scheme to 1.92 million. The Pre-IPO Share Option Scheme maintained 2.13 million options outstanding. No options were exercised, so share count and cash balance were unaffected.

• Restricted Share Unit (RSU) programmes recorded no share issuances or transfers. Unallocated pools comprise up to 0.44 million shares under the 2021 RSU Scheme and 4.33 million shares under the 2022 RSU Scheme. The legacy 2019 RSU Scheme retains its 5.27 million-share limit, all of which remain unissued.

• The company confirmed adherence to all regulatory requirements, including receipt of all funds due and fulfilment of listing conditions for any securities-related activities during the period.

Overall, Ascentage Pharma’s June filing highlights capital structure stability, ongoing compliance with public float rules, and moderate movements confined to option grants without share dilution.